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There have been many treatments suggested for the management of mastalgia; one of these
is the fruit extract of Vitex Agnus castus L. commonly known as Agnus castus, an extract of
a deciduous shrub native to Mediterranean Europe and Central Asia. It is postulated that
A. castus suppresses the stress-induced latent hyperprolactinemia which is a release of supra-
physiological levels of prolactin in some patients in response to stressful stimuli. It is postulated
that A. castus could be effective in the treatment of cyclical mastalgia by inhibiting the release
of excess prolactin by blocking Dopamine-2 receptor type on pituitary. The adverse events
following A. castus treatment are mild and reversible. The aim of this review is assess the
efficacy of A. castus in the treatment of mastalgia. Data from randomized and non-randomized
studies regarding the efficacy and safety of A. castus is reviewed in a systematic fashion. It is
concluded that A. castus can be considered as an efficient alternative phytotherapeutic agent
in the treatment of mastalgia.
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Introduction
Mastalgia is a multi-faceted and inhomogeneous clinical
condition with poorly understood etiology. Between 50%
and 80% of women are estimated to have experienced
mastalgia at some point in their life but in only 1% of
patients is mastalgia a symptom of breast cancer. Chronic
or recurrent mastalgia and lack of reliable remedies
can lead to severe impact on a patient’s quality of life.
Psychological morbidity such as depression, helplessness
and loss of self-esteem in patients suffering from
mastalgia are well documented (1).
There have been many treatments suggested for the
management of mastalgia; one of these is the fruit extract
of Vitex Agnus castus L. commonly known as Agnus
castus, a deciduous shrub native to Mediterranean
Europe and Central Asia. The use of herbal treatments
in the management of pain is well documented (2). Agnus
castus, like other herbal treatments (3), has been used in
the treatment of many conditions of women’s health such
as menstrual disorders (amenorrhea, dysmenorrhea),
premenstrual syndrome, corpus luteum insufficiency,
hyperprolactinemia, infertility, acne, menopause and
disrupted lactation (4–12). Agnus castus is thought to
be affective in the management of mastalgia because of
its dopminergic effects. It is postulated that A. castus
suppresses the stress-induced latent hyperprolactinemia in
patients suffering from cyclical mastalgia. The purpose of
this review is to analyze the current evidence available for
the efficacy and safety of A. castus in the management of
mastalgia.
Mechanism of Action?
The reasons why A. castus could be helpful in the
management of mastalgia may be because of its effect on
latent hyperprolactinemia, estrogen receptors or other
unknown mechanisms.
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There is evidence to suggest that cyclical mastalgia in
some women is caused by a latent stress-induced
hyperprolactinemia (13,14). Some women respond to
stimuli of prolactin release with a hyper-secretion of
this hormone resulting in stimulation of mammary gland
leading to cyclical mastalgia. Agnus castus may have
therapeutic role in the management of cyclical mastalgia
by controlling hyper-secretion of prolactin. The ability to
lower the prolactin level in women with cyclical mastalgia
has been shown in clinical and laboratory studies (15–17).
A prolactin-suppressive effect of A. castus is thought to
be due to a number of diterpenes including clerodadie-
nols (15). These compounds manifest their dopminergic
properties by binding to recombinant DA2-receptor
protein, which has been shown to suppress prolactin
release from cultivated lactotrophs and also in-vivo in
animal experiments. These substances are almost identical
in their prolactin-suppressive properties as dopamine
itself (15). Addition of A. castus significantly inhibits
basal as well as TRH-stimulated prolactin secretion of rat
pituitary cells in vitro, as demonstrated in the primary cell
culture experiments (18). These experiments also found
that adding a dopamine receptor blocker could prevent
this A. castus-induced inhibition of prolactin secretion.
Authors suggested that because of its dopaminergic effect
A. castus could be considered as an efficient alternative
phytotherapeutic drug in the treatment of hyperprolacti-
nemia. Other studies have demonstrated that inhibition
of prolactin secretion by A. castus is dependent on the
initial level of prolactin and the dose of A. castus and is
independent of gonadotrophins (19,20).
Estrogen Binding
It is postulated that A. castus may interact with steroid
hormones in order to reduce breast pain in some women.
The role of estrogen in the development of breast pain
is not clearly understood but anti-estrogen medication
has shown to have a significant effect on the improve-
ment of breast pain (21–24). It is possible that A. castus
may block estrogen receptors by binding to these
receptors and exert anti-estrogen activity. Experimental
evidence found that A. castus demonstrates a significant
competitive binding to estrogen receptors alpha
(ER alpha) and beta (ER beta) as well as stimulating
Progesterone Receptor expression (25). The exact
mechanism of this increased affinity to estrogen receptors
is not well understood but is thought to be mediated by
yet unidentified phytoestrogens (15,26). Clinically,
anti-estrogenic medication helps with breast pain.
However, there is no evidence to support that A. castus
has anti-estrogenic activity and in fact it may have weak
estrogenic activity. Therefore it is possible that the
estrogen binding function of A. castus may not contribute
to the ability of A. castus to alleviate mastodynia.
Apigenin has increased binding activity to ER beta,
which appears to be involved in regulation of the
mammary fat tissue, but has no effect on uterus and
only little effect on bones (15). Agnus castus has also been
shown to be able to up-regulate pS2 (presenelin-2),
an estrogen-inducible gene in S30 breast cancer cells.
Therefore, it is possible that A. castus may preferentially
bind with estrogen receptors hence controlling mastalgia
by blocking estrogenic activity of the breast cells by yet
unknown mechanisms. Further experimental studies
suggest that linoleic acid from the fruits of Vitex A.
castus can bind to estrogen receptors and induce certain
estrogen inducible genes. However, linoleic acid was
found to have estrogenic affinity only at a very
high concentration for a single compound (25–30mM),
and therefore it is unlikely that this compound is
responsible for any therapeutic activity in vivo. (27).
As estrogen can exert its effect on the mammary
epithelial cells by genomic and non-genomic pathways
the exact mechanism by which estrogen affects breast
pain is not clearly understood.
Safety of Agnus Castus
The most frequent adverse events associated with the
use of A. castus are nausea, headache, gastrointestinal
disturbances, menstrual disorders, acne, pruritus and
erythematous rash. Data available from clinical trials,
post-marketing surveillance studies, surveys, spontaneous
reporting schemes, manufacturers and herbalist organiza-
tions have recently been reviewed (28). The adverse
events following A. castus treatment are mild and
reversible indicating that A. castus is a safe herbal
medicine. (28). Data of The German Commission E has
approved the use of A. castus for mastalgia. No drug
interactions have been reported.
Evidence that Agnus castus is Useful
for Mastalgia?
The evidence of effectiveness of A. castus in the
management of mastalgia is available from both rando-
mized and non-randomized studies. This evidence is
summarized in Table 1.
Non-Randomized Studies
A large scale multi-centric non-interventional trial
(open study without control) of 1634 patients suffering
from cyclical mastalgia as a part of premenstrual
syndrome, revealed that frequency and severity of cyclical
mastalgia decreased after 3 months of therapy with
A. castus. (6,29). Eighty percent of physicians and 81%
of patients rated A. castus as good or very good
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assessed the tolerance of A. castus treatment as good or
very good. There were no serious adverse reactions to
A. castus and minor adverse reactions were observed in
1% of patients. Authors suggested that A. castus could be
useful in the management of cyclical mastalgia.
In a prospective, multi-centre trial the efficacy of
A. castus in the management of cyclical mastalgia
was investigated in 50 patients with pre-menstrual
syndrome (30). Forty-three patients were treated daily
with A. castus during three menstrual cycles. At the end
of the study, cyclical mastalgia decreased significantly
and a smaller degree of improvement (20%) persisted
even 3 months after cessation of the treatment.
(P50.001). At baseline, the A. castus score was elevated
in the late luteal phase and low at the follicular phase,
as expected. During treatment, A. castus score decreased
in the late luteal phase (47%; P50.01) and remained
22% (P50.001) below baseline after 3 cycles post-
cessation of treatment. Thirty-eight patients judged the
global efficacy moderate to excellent, 5 patients indicated
no global efficacy. Twenty (47%) patients reported 37
minor adverse events none of which was serious.
Randomized Control Trials
Agnus castus was well tolerated and was effective in
controlling the symptoms of cyclical mastalgia in
a placebo-controlled, randomized, double-blind study
of 97 patients suffering from cyclical mastalgia (31).
The intensity of mastalgia in patients treated with
A. castus as measured by visual analogue score signifi-
cantly decreased after one or two treatment cycles and
remained reduced after third cycle. After one/two
treatment cycles mean visual analogue score decreased
by 21mm/34mm in A. castus group (n¼48) as compared
with 11mm/20mm for the placebo group (n¼49)
(P¼0.018; P¼0.006). Visual analogue score was less
than 35 in 71% of patients after two treatment cycles.
Not only the intensity but duration of pain also improved
on A. castus treatment. In A. castus group, 50% of
patients did not have severe pain at all during menstrual
cycle and only 25% had severe pain for 4% of days
compared with severe mastalgia for 20% of days before
treatment. There was no difference in the frequency of
adverse events between both groups (A. castus: n¼5;
placebo: n¼4).
The efficacy of A. castus for the treatment of
cyclical mastalgia associated with premenstrual dysphoric
disorder was compared with fluoxetine, a selective
serotonin reuptake inhibitor (SSRI), in a randomized
control trial (32). After a period of 2 months to
screen the patients for suitability, 41 patients were
randomized to fluoxetine or A. castus for 2 months of
single-blind, rater-blinded and prospective treatment
period. In patients treated with A. castus, cyclical
mastalgia improved by 450%. Psychological symptoms
improved in 68% of patients treated with Fluoxetine
and mastalgia improved in 58% of patients treated with
A. castus.
A randomized, double-blind, placebo controlled trial
and parallel group comparison was carried out in 170
women who were given A. castus or placebo for three
consecutive cycles (active 86; placebo 84) (33). Mean age
of women was 36 years. The study demonstrated that the
improvement in breast pain was greater in the A. castus
group compared with placebo group (52% versus 24%,
P50.001). Seven women reported mild adverse events
(four active; three placebo), none of which caused
discontinuation of treatment. The authors concluded
that A. castus is an effective and well-tolerated treatment
for the relief of symptoms of mastalgia associated with
premenstrual syndrome.
Data from randomized and non-randomized well-
conducted studies provides convincing evidence to
suggest that A. castus is safe, effective and well tolerated
in a majority of patients suffering from mastalgia.
Therefore, use of A. castus is justified in the treatment
of cyclical mastalgia for at least three cycles.
Conclusion
There is convincing laboratory-based and clinical
evidence available that A. castus is safe, effective and
efficient in the treatment of cyclical mastalgia. It has
a safe side effect profile and can be used safely for
the treatment of cyclical mastalgia.
Table 1. Evidence that Vitex Agnus Castus is useful in the management of cyclical mastalgia
Author and
Reference
Study
type
Duration of
treatment
Patients Age Pain
assessment
Outcome Adverse
reaction
Loch (29) Cohort 3 Months 1634 36 (9) Questionnaire 85% reduction 1%
Halaska (31) RCT with placebo 3 Months VAC 48 Placebo 49 36 (6) VAS 54% reduction 5/48 4/49
Atmaca (32) RCT with Fluoxetine 2 Months VAC 20 Fluoxetine 21 33 (11) HAM-D DSR CGI-SI 50% reduction
Berger (30) Cohort 3 Months 50 31 (8) VAS 45% reduction 20/50
Schellenberg (33) RCT with placebo 3 Months VAC 86 Placebo 84 36 DMS-III-R 52% reduction 4/86 3/84
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